Ratings by William Blair (Sami Corwin)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 2/23/2026 | Arcellx Inc. | ACLX | Downgrade | Market Perform (Outperform) |
64.11 (114.33) |
78.33% | Details | |
| 2/10/2026 | Tyra Biosciences | TYRA | New Coverage | Outperform (N/A) |
30.50 (35.04) |
14.89% | Details | |
| 12/29/2025 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2025 | uniQure BV | QURE | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/4/2025 | uniQure BV | QURE | Downgrade | Market Perform (Outperform) |
67.69 (14.27) |
-78.92% | Details | |
| 8/20/2025 | Kyverna Therapeutics Inc | KYTX | New Coverage | Outperform (N/A) |
3.30 (8.10) |
145.45% | Details | |
| 7/21/2025 | Sarepta Therapeutics | SRPT | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/18/2025 | Sarepta Therapeutics | SRPT | Maintain | Market Perform (N/A) |
|
Details | ||
| 6/26/2025 | CRISPR Therapeutics | CRSP | Maintain | Outperform (N/A) |
|
Details | ||
| 6/23/2025 | PTC Therapeutics | PTCT | Maintain | Outperform (N/A) |
|
Details | ||
| 6/20/2025 | Sarepta Therapeutics | SRPT | Downgrade | Market Perform (Outperform) |
20.77 (16.71) |
-19.55% | Details | |
| 5/28/2025 | Ultragenyx Pharma | RARE | New Coverage | Outperform (N/A) |
35.08 (21.25) |
-39.42% | Details | |
| 5/27/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/15/2025 | Nkarta Inc. | NKTX | Downgrade | Market Perform (Outperform) |
1.94 (2.50) |
28.87% | Details | |
| 1/30/2025 | Cargo Therapeutics | CRGX | Downgrade | Market Perform (Outperform) |
13.19 (4.47) |
-66.11% | Details | |
| 12/23/2024 | Applied Therapeutics | APLT | Downgrade | Market Perform (Outperform) |
0.88 (0.10) |
-88.64% | Details | |
| 11/26/2024 | Cargo Therapeutics | CRGX | New Coverage | Outperform (N/A) |
16.42 (13.19) |
-19.67% | Details | |
| 6/10/2024 | Tenaya Therapeutics Inc | TNYA | New Coverage | Outperform (N/A) |
3.64 (0.89) |
-75.55% | Details | |
| 3/21/2024 | Neurogene | NGNE | New Coverage | Outperform (N/A) |
44.80 (22.17) |
-50.51% | Details | |
| 11/29/2023 | Cabaletta Bio Inc. | CABA | New Coverage | Outperform (N/A) |
13.69 (3.17) |
-76.84% | Details | |
| 5/30/2023 | CRISPR Therapeutics | CRSP | New Coverage | Outperform (N/A) |
64.66 (56.50) |
-12.62% | Details | |
| 5/25/2023 | Legend Biotech Corp. | LEGN | New Coverage | Market Perform (N/A) |
66.04 (18.97) |
-71.27% | Details | |
| 10/18/2022 | Akouos | AKUS | Downgrade | Market Perform (Outperform) |
7.01 (13.29) |
89.59% | Details | |
| 9/29/2022 | Akouos | AKUS | New Coverage | Outperform (N/A) |
5.39 (13.29) |
146.57% | Details | |
| 5/12/2022 | Century Therapeutics | IPSC | New Coverage | Market Perform (N/A) |
8.08 (2.56) |
-68.32% | Details |
